# Eluxadoline Bile Acid Malabsorption (BAM) Study

> **NCT03441581** · PHASE4 · COMPLETED · sponsor: **Allergan** · enrollment: 24 (actual)

## Conditions studied

- Irritable Bowel Syndrome With Diarrhea

## Interventions

- **DRUG:** Eluxadoline

## Key facts

- **NCT ID:** NCT03441581
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-23
- **Primary completion:** 2020-04-28
- **Final completion:** 2020-04-28
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2021-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03441581

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03441581, "Eluxadoline Bile Acid Malabsorption (BAM) Study". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03441581. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*